Paper34367161
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z and 3 others. Front Immunol, 2021. Cited by 199 papers, by iCite.
Cite this record
ConductScience Library. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. Papers, record 34367161. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34367161
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Immunotherapy | Major topic |
| Neoplasms | Major topic |
| Receptors, Immunologic | Major topic |
| Animals | |
| Humans |
Source PubMed
References101
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23330003 | Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. | Int J Clin Exp Pathol | 2013 | https://conductscience.org/library/papers/23330003 | PubMed |
| 2 | 29794465 | Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy. | Cell Physiol Biochem | 2018 | https://conductscience.org/library/papers/29794465 | PubMed |
| 3 | 33045061 | PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. | J Exp Med | 2021 | https://conductscience.org/library/papers/33045061 | PubMed |
| 4 | 32345648 | Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32345648 | PubMed |
| 5 | 32716559 | Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer. | Hepatology | 2021 | https://conductscience.org/library/papers/32716559 | PubMed |
| 6 | 32265229 | CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. | Cancer Immunol Res | 2020 | https://conductscience.org/library/papers/32265229 | PubMed |
| 7 | 31234588 | DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31234588 | PubMed |
| 8 | 29025772 | Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. | Cancer Discov | 2017 | https://conductscience.org/library/papers/29025772 | PubMed |
| 9 | 11437656 | The poliovirus receptor CD155 mediates cell-to-matrix contacts by specifically binding to vitronectin. | Virology | 2001 | https://conductscience.org/library/papers/11437656 | PubMed |
| 10 | 25934860 | PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells. | J Immunol | 2015 | https://conductscience.org/library/papers/25934860 | PubMed |
| 11 | 33224630 | TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. | Oncoimmunology | 2020 | https://conductscience.org/library/papers/33224630 | PubMed |
| 12 | 32591463 | IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32591463 | PubMed |
| 13 | 32269065 | Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS. | Neurol Neuroimmunol Neuroinflamm | 2020 | https://conductscience.org/library/papers/32269065 | PubMed |
| 14 | 28434648 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. | Lancet | 2017 | https://conductscience.org/library/papers/28434648 | PubMed |
| 15 | 28258692 | LAG3 (CD223) as a cancer immunotherapy target. | Immunol Rev | 2017 | https://conductscience.org/library/papers/28258692 | PubMed |
| 16 | 20331633 | Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. | Cancer Sci | 2010 | https://conductscience.org/library/papers/20331633 | PubMed |
| 17 | 22427644 | The TIGIT/CD226 axis regulates human T cell function. | J Immunol | 2012 | https://conductscience.org/library/papers/22427644 | PubMed |
| 18 | 30659055 | Mouse PVRIG Has CD8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity. | Cancer Immunol Res | 2019 | https://conductscience.org/library/papers/30659055 | PubMed |
| 19 | 17875681 | The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. | Cancer Res | 2007 | https://conductscience.org/library/papers/17875681 | PubMed |
| 20 | 33781741 | TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. | Cell Mol Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/33781741 | PubMed |
Cited by168
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 199 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42969235 | TARBP2 facilitates renal cell carcinoma immune escape by suppressing 53BP1 phase separation to upregulate B7-H3. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42969235 | PubMed |
| 42968166 | Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact. | J Transl Med | 2026 | https://conductscience.org/library/papers/42968166 | PubMed |
| 42944788 | CD226⁺TIGIT⁺ MAIT cells exhibit an increased relative frequency and a checkpoint-enriched phenotype in Sjögren's disease. | Clin Rheumatol | 2026 | https://conductscience.org/library/papers/42944788 | PubMed |
| 42940206 | Phenotypic Landscape of Programmed Death and TIGIT/CD155/DNAM-1 Pathways in NK Cells in Ovarian Cancer. | Biomedicines | 2026 | https://conductscience.org/library/papers/42940206 | PubMed |
| 42719683 | Tumor microenvironment-mediated resistance to immune checkpoint inhibitors in non-small cell lung cancer: Mechanisms, combination strategies and clinical perspectives (Review). | Mol Clin Oncol | 2026 | https://conductscience.org/library/papers/42719683 | PubMed |
| 42694449 | The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42694449 | PubMed |
| 42675035 | Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42675035 | PubMed |
| 42654087 | The Right Key, the Wrong Lock: TIGIT Checkpoint Blockade and the Road to Precision Immunotherapy. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42654087 | PubMed |
| 42486610 | Intratumoral TIGIT blockade augments antitumor responses and bypasses increased functionality of peripheral TIGIT+ NK cells in mouse and human models of bone and soft tissue sarcoma. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42486610 | PubMed |
| 42389526 | Fusion protein-mediated costimulation in engineered T cells: from intrinsic signaling to tumor microenvironment rewiring. | Front Immunol | 2026 | https://conductscience.org/library/papers/42389526 | PubMed |
| 42382468 | PD-1/TIGIT CD4⁺ T-Cell Signature for Risk Stratification of Post-Weaning Mortality in Venoarterial Extracorporeal Membrane Oxygenation Patients. | J Inflamm Res | 2026 | https://conductscience.org/library/papers/42382468 | PubMed |
| 42353619 | Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42353619 | PubMed |
| 42353092 | Beyond PD-1/PD-L1: Reprogramming the Gynecologic Tumor Microenvironment by Targeting TIGIT and Myeloid Suppression. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353092 | PubMed |
| 42338241 | Immune Checkpoints in Leukaemia as Gatekeepers of Immuno-Modulation. | Immunology | 2026 | https://conductscience.org/library/papers/42338241 | PubMed |
| 42317269 | Precision immuno-oncology in oral cancer: latest trends in biomarkers, novel drug development and nanoparticle-based therapeutic platforms. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42317269 | PubMed |
| 42249376 | Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42249376 | PubMed |
| 42237330 | TRIM71 suppresses cervical cancer progression by inhibiting Nectin4-mediated Wnt/β-catenin signaling. | Biol Direct | 2026 | https://conductscience.org/library/papers/42237330 | PubMed |
| 42176073 | Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/42176073 | PubMed |
| 42174730 | CD155 and its receptors in glioma: prospects for emerging immune checkpoint inhibitors. | Acta Neuropathol Commun | 2026 | https://conductscience.org/library/papers/42174730 | PubMed |
| 42136664 | The mechanisms of regulatory T cells in the immune microenvironment of multiple myeloma and clinical significance. | Front Immunol | 2026 | https://conductscience.org/library/papers/42136664 | PubMed |
Genes37
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34367161
GET https://conductscience.org/api/papers/v1/34367161/references?page=2